Clinical trial
Effects of a CB1 Receptor Antagonist/Inverse Agonist (Rimonabant) on Walking Ability in Patients in the Chronic Phase of Stroke (RIMOSTROKE-1)
NCT07913763 is registered in ClinicalTrials.gov with Sinfatin S.L as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- Effects of a CB1 Receptor Antagonist/Inverse Agonist (Rimonabant) on Walking Ability in Patients in the Chronic Phase of Stroke (RIMOSTROKE-1)
- Lead sponsor
- Sinfatin S.L
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- November 30, 2026
- Completion date
- December 31, 2028
- Enrollment
- 80 (estimated)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.
chronic stroke
Arms
As registered; 2 arms.
-
Rimonabant 5 mg
Participants randomized to receive rimonabant 5 mg.
-
Placebo
Participants randomized to receive matching placebo.
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Six-Minute Walk Test (6MWT)
The 6MWT assesses walking capacity by measuring the distance walked in six minutes, expressed in meters. The primary endpoint is the percentage change in walking distance from baseline to the end of follow-up on day 135. Greater distances indicate better walking capacity.
Lead sponsor's other trials
Sinfatin S.L, most recent start first.